• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Verapamil pharmacodynamics after intravenous and oral dosing: theoretic consideration.

作者信息

Colburn W A, Brazzell R K, Holazo A A

出版信息

J Clin Pharmacol. 1986 Jan;26(1):71-3. doi: 10.1002/j.1552-4604.1986.tb02906.x.

DOI:10.1002/j.1552-4604.1986.tb02906.x
PMID:3950053
Abstract

Differences in the potency of intravenous (IV) and oral verapamil have recently been reported with the concentration-response curve for PR-interval prolongation being shifted further to the right following oral administration relative to IV administration. Using well-established pharmacokinetic models, a theoretic basis for these observations is presented. Simultaneous curve fitting of the IV and oral verapamil plasma concentration and PR-interval data to a single pharmacokinetic-pharmacodynamic model allowed prediction of differences in the pharmacodynamic potency of verapamil as a function of the rate of drug administration. These data indicate that the rate of input of drug into the systemic circulation can influence the rate and extent of entry of drug into an effect compartment, which in turn can result in different plasma concentration-response relationships.

摘要

相似文献

1
Verapamil pharmacodynamics after intravenous and oral dosing: theoretic consideration.
J Clin Pharmacol. 1986 Jan;26(1):71-3. doi: 10.1002/j.1552-4604.1986.tb02906.x.
2
Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects.维拉帕米与普萘洛尔在正常受试者中潜在药效学和药代动力学相互作用的评估。
Br J Clin Pharmacol. 1991 Mar;31(3):323-32. doi: 10.1111/j.1365-2125.1991.tb05536.x.
3
Verapamil disposition and cardiovascular effects in elderly patients after single intravenous and oral doses.老年患者单次静脉注射和口服维拉帕米后的药物处置及心血管效应
Cardiovasc Drugs Ther. 1989 Jun;3(3):417-25. doi: 10.1007/BF01858113.
4
The pharmacodynamic and pharmacokinetic differences of the D- and L-isomers of verapamil: implications in the treatment of paroxysmal supraventricular tachycardia.
Am Heart J. 1986 Aug;112(2):396-403. doi: 10.1016/0002-8703(86)90281-4.
5
Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin.利福平对维拉帕米肝前代谢和肝脏代谢的差异诱导作用。
Hepatology. 1996 Oct;24(4):796-801. doi: 10.1002/hep.510240407.
6
Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism.消旋维拉帕米对房室传导的影响及其立体选择性首过代谢的关系。
Clin Pharmacol Ther. 1985 Jul;38(1):71-6. doi: 10.1038/clpt.1985.137.
7
Pharmacokinetics and pharmacodynamics of verapamil following sublingual and oral administration to healthy volunteers.健康志愿者舌下和口服维拉帕米后的药代动力学和药效学
Br J Clin Pharmacol. 1992 Jun;33(6):623-7. doi: 10.1111/j.1365-2125.1992.tb04091.x.
8
Influence of cimetidine on verapamil kinetics and dynamics.
Clin Pharmacol Ther. 1984 Oct;36(4):551-4. doi: 10.1038/clpt.1984.218.
9
The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses.
Clin Pharmacol Ther. 1982 Apr;31(4):418-26. doi: 10.1038/clpt.1982.54.
10
Comparison of intravenous and oral verapamil dosing.
Clin Pharmacol Ther. 1982 Dec;32(6):711-20. doi: 10.1038/clpt.1982.227.

引用本文的文献

1
Pharmacokinetic-pharmacodynamic model for fantofarone cardiac and brachial haemodynamic effects in healthy volunteers.法托法隆对健康志愿者心脏和肱动脉血流动力学影响的药代动力学-药效学模型。
Br J Clin Pharmacol. 1999 Dec;48(6):801-10. doi: 10.1046/j.1365-2125.1999.00091.x.
2
Mathematical model for in vivo pharmacodynamics integrating fluctuation of the response: application to the prolactin suppressant effect of the dopaminomimetic drug DCN 203-922.整合反应波动的体内药效学数学模型:在多巴胺模拟药物DCN 203-922催乳素抑制作用中的应用
J Pharmacokinet Biopharm. 1991 Jun;19(3):287-309. doi: 10.1007/BF03036252.